+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

In-vivo efficacy of novel paclitaxel nanoparticles in paclitaxel-resistant human colorectal tumors



In-vivo efficacy of novel paclitaxel nanoparticles in paclitaxel-resistant human colorectal tumors



Journal of Controlled Release 112(3): 312-319



Colloidal carriers have been shown to improve tumor therapy by increased drug delivery into tumor sites resulting directly from the enhanced permeability and retention effect (EPR). However, the clinical outcome of tumor therapy is often limited due to multidrug resistance. Several different types of resistance exist with expression of p-glycoprotein being the most commonly described. Paclitaxel entrapped in emulsifying wax nanoparticles (PX NPs) was shown to overcome drug resistance in a human colon adenocarcinoma cell line (HCT-15). In the present studies, the in-vivo efficacy of PX NPs in a HCT-15 mouse xenograft model was demonstrated. Significant inhibition in tumor growth was observed in mice receiving PX NPs treatment. Additionally, mice dosed with Taxol also demonstrated slower tumor growth; however, the efficacy of the Taxol treatment was shown in the in-vitro HUVEC model to be due to the antiangiogenic effect of paclitaxel. It was concluded that the enhanced efficacy of PX NPs over Taxol in the xenograft model was due to both overcoming paclitaxel resistance and an antiangiogenic effect.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 012195630

Download citation: RISBibTeXText

PMID: 16626835

DOI: 10.1016/j.jconrel.2006.03.001


Related references

Free paclitaxel loaded PEGylated-paclitaxel nanoparticles: preparation and comparison with other paclitaxel systems in vitro and in vivo. International Journal of Pharmaceutics 471(1-2): 525-535, 2015

Radiosensitization by paclitaxel. The in-vivo results in paclitaxel-sensitive and -resistant tumors. Strahlentherapie und Onkologie 174(10): 539-540, 1998

D-24851, a novel synthetic tubulin inhibitor, exerts superior in vivo antitumoral activity to paclitaxel or vincristine, efficacy against multidrug resistant tumors, and lacks neurotoxicity. Proceedings of the American Association for Cancer Research Annual Meeting (41): 303, March, 2000

Reconstituted high density lipoprotein mediated targeted co-delivery of HZ08 and paclitaxel enhances the efficacy of paclitaxel in multidrug-resistant MCF-7 breast cancer cells. European Journal of Pharmaceutical Sciences 92: 11-21, 2017

Paclitaxel in tyrosine-derived nanospheres as a potential anti-cancer agent: in vivo evaluation of toxicity and efficacy in comparison with paclitaxel in Cremophor. European Journal of Pharmaceutical Sciences 45(3): 320-329, 2012

Silibinin restores paclitaxel sensitivity to paclitaxel-resistant human ovarian carcinoma cells. Anticancer Research 28(2a): 1119-1127, 2008

Paclitaxel (Taxol(R)) inhibits motility of paclitaxel-resistant human ovarian carcinoma cells. Clinical Cancer Research 2(10): 1725-1730, 1996

Identification of paclitaxel analogs with activity in paclitaxel resistant human ovarian carcinoma cell lines. International Journal of Oncology 7(SUPPL ): 1001, 1995

Cross-reacting material 197 reverses the resistance to paclitaxel in paclitaxel-resistant human ovarian cancer. Tumour Biology 37(4): 5521-5528, 2017

Overexpression of alpha tubulins in paclitaxel treated and paclitaxel resistant human cancer cell lines. Proceedings of the American Association for Cancer Research Annual Meeting 39: 190, March, 1998

Emodin sensitizes paclitaxel-resistant human ovarian cancer cells to paclitaxel-induced apoptosis in vitro. Oncology Reports 21(6): 1605-1610, 2009

Antitumor efficacy of a paclitaxel analogue, IDN5109, on human ovarian carcinoma xenografts with different sensitivity to paclitaxel. Proceedings of the American Association for Cancer Research Annual Meeting 40: 288, March, 1999

Paclitaxel-resistant human ovarian cancer cells have mutant b-tubulins that exhibit impaired paclitaxel-driven polymerization. The Journal of Biological Chemistry 272: 118-25, 1997

Low-dose suramin enhanced paclitaxel activity in chemotherapy-naive and paclitaxel-pretreated human breast xenograft tumors. Clinical Cancer Research 10(18 Pt 1): 6058-6065, 2004

Establishment of a paclitaxel resistant human breast cancer cell strain (MCF-7/Taxol) and intracellular paclitaxel binding protein analysis. Journal of International Medical Research 38(4): 1428-1435, 2010